In a prospective study , consecutive patients with decompensated cirrhosis seen at the Institute of Liver and Biliary Sciences , New Delhi ( from May 2011 through June 2012 ) were randomly assigned to groups given subcutaneous G-CSF ( 5 g/kg/d ) for 5 days and then every third day ( 12 total doses ) , along with subcutaneous darbopoietin ( 40 mcg/wk ) for 4 weeks ( GDP group , n = 29 ) , or only placebos ( control group , n = 26 ) .